Q32 Bio Inc (QTTB)

$5.72 +0.25 (4.57%)
Market Cap 90.99M
Revenue (ttm) 53.74M
Net Income (ttm) 29.82M
EPS (ttm) N/A
PE Ratio 4.73
Forward PE N/A
Profit Margin 55.49%
Debt to Equity Ratio 0.23
Volume 165,075
Avg Vol 302,690
Day's Range N/A - N/A
Shares Out 14.63M
Stochastic %K 45%
Beta -0.05
Analysts Strong Sell
Price Target $14.33

Company Profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 999 0232
Address:
830 Winter Street, Waltham, United States
ash1012
ash1012 Apr. 27 at 2:45 PM
$QTTB tomo this will be $4.00
0 · Reply
McLarkin
McLarkin Apr. 27 at 1:44 PM
$QTTB they gotta raise after the AA readout coming imminently, so ATM used prudently is actully the ideal scenario instead of discounted offers to institutions - many who may avoid this is too small a Cap... so I'm supportive here..
1 · Reply
NotHopeJustFacts
NotHopeJustFacts Apr. 27 at 12:46 PM
$QTTB more dilution for a company that pretend to sell overpriced shampoo for bold people ? this is worthless and, after their failure with eczema, a scam
0 · Reply
Olivia_Strickland
Olivia_Strickland Apr. 24 at 10:03 PM
$QTTB down 14.64% AH after filing for a fresh $75M ATM offering. dilution stings on a $78M cap, that's basically the whole company. order book stacked 8x on the ask, no surprise. not touching this until the bleed stops.
2 · Reply
ffienimi
ffienimi Apr. 24 at 9:27 PM
$QTTB Q32 Bio filed a new prospectus supplement to sell up to USD 75 million of common stock through its at-the-market program with Cantor Fitzgerald. * Company completed its prior ATM tranche, selling USD 14.2 million of common stock under the earlier prospectus supplement. * Sales will continue under the existing Controlled Equity Offering sales agreement signed March 27, 2026. * Additional shares will be issued off Q32 Bio’s effective Form S-3 shelf registration statement
0 · Reply
GoCoogs
GoCoogs Apr. 24 at 9:20 PM
$QTTB WTH is going on with this after-hours?
0 · Reply
scoon42
scoon42 Apr. 21 at 1:26 PM
$QTTB $8 incoming today IMO!
0 · Reply
Stef_DL
Stef_DL Apr. 21 at 12:58 PM
$QTTB A lot of live in the green party. Let's see what this bring at opening 🤔.
0 · Reply
STACKD0E
STACKD0E Apr. 21 at 12:35 PM
$QTTB $SLDP $PRLD $LOBO
1 · Reply
scoon42
scoon42 Apr. 21 at 12:09 PM
$QTTB Something’s Brewing!
0 · Reply
Latest News on QTTB
Q32 Bio Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 12:45 PM EDT - 13 days ago

Q32 Bio Transcript: 25th Annual Needham Virtual Healthcare Conference

Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 6:59 AM EDT - 20 days ago

Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Mar 10, 2026, 6:59 AM EDT - 7 weeks ago

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 2:00 PM EST - 2 months ago

Q32 Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 6:59 AM EST - 2 months ago

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Q32 Bio Announces $10.5 Million Registered Direct Offering

Feb 17, 2026, 6:59 AM EST - 2 months ago

Q32 Bio Announces $10.5 Million Registered Direct Offering

Dow Dips 200 Points; Q32 Bio Shares Jump

Dec 1, 2025, 9:58 AM EST - 5 months ago

Dow Dips 200 Points; Q32 Bio Shares Jump

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Dec 1, 2025, 9:43 AM EST - 5 months ago

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Q32 Bio Sells Complement Inhibitor ADX-097

Dec 1, 2025, 7:00 AM EST - 5 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

AKBA

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 6:59 AM EST - 5 months ago

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Oct 21, 2025, 6:59 AM EDT - 6 months ago

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 3:45 PM EDT - 8 months ago

Q32 Bio Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 28, 2025, 6:59 AM EDT - 8 months ago

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 6:59 AM EDT - 9 months ago

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Jun 25, 2025, 6:59 AM EDT - 10 months ago

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 6:59 AM EDT - 1 year ago

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Apr 30, 2025, 6:59 AM EDT - 1 year ago

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Apr 16, 2025, 6:59 AM EDT - 1 year ago

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Q32 Bio Transcript: Leerink Global Healthcare Conference 2025

Mar 11, 2025, 11:20 AM EDT - 1 year ago

Q32 Bio Transcript: Leerink Global Healthcare Conference 2025

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Mar 11, 2025, 6:59 AM EDT - 1 year ago

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Mar 8, 2025, 11:00 AM EST - 1 year ago

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Q32 Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 11:50 AM EST - 1 year ago

Q32 Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Feb 28, 2025, 9:00 AM EST - 1 year ago

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Q32 Bio to Participate in Upcoming March Investor Conferences

Feb 26, 2025, 6:59 AM EST - 1 year ago

Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 4:00 PM EST - 1 year ago

Q32 Bio Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Feb 10, 2025, 4:05 PM EST - 1 year ago

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 1 year ago

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Dec 11, 2024, 11:32 AM EST - 1 year ago

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Dec 10, 2024, 4:05 PM EST - 1 year ago

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Nov 12, 2024, 10:00 AM EST - 1 year ago

Q32 Bio Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 6:59 AM EST - 1 year ago

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 6:59 AM EST - 1 year ago

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Oct 14, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio Transcript: Stifel 2024 Immunology and Inflammation Virtual Summit

Sep 18, 2024, 11:30 AM EDT - 1 year ago

Q32 Bio Transcript: Stifel 2024 Immunology and Inflammation Virtual Summit

Q32 Bio Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 3:40 PM EDT - 1 year ago

Q32 Bio Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Q32 Bio to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Participate in Upcoming September Investor Conferences

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

Aug 1, 2024, 4:54 PM EDT - 1 year ago

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

EBS HE HUMA SERV

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Jul 9, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Q32 Bio Joins Russell 3000® Index

Jul 1, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Joins Russell 3000® Index

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 6:59 AM EDT - 2 years ago

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

Mar 25, 2024, 4:15 PM EDT - 2 years ago

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

ash1012
ash1012 Apr. 27 at 2:45 PM
$QTTB tomo this will be $4.00
0 · Reply
McLarkin
McLarkin Apr. 27 at 1:44 PM
$QTTB they gotta raise after the AA readout coming imminently, so ATM used prudently is actully the ideal scenario instead of discounted offers to institutions - many who may avoid this is too small a Cap... so I'm supportive here..
1 · Reply
NotHopeJustFacts
NotHopeJustFacts Apr. 27 at 12:46 PM
$QTTB more dilution for a company that pretend to sell overpriced shampoo for bold people ? this is worthless and, after their failure with eczema, a scam
0 · Reply
Olivia_Strickland
Olivia_Strickland Apr. 24 at 10:03 PM
$QTTB down 14.64% AH after filing for a fresh $75M ATM offering. dilution stings on a $78M cap, that's basically the whole company. order book stacked 8x on the ask, no surprise. not touching this until the bleed stops.
2 · Reply
ffienimi
ffienimi Apr. 24 at 9:27 PM
$QTTB Q32 Bio filed a new prospectus supplement to sell up to USD 75 million of common stock through its at-the-market program with Cantor Fitzgerald. * Company completed its prior ATM tranche, selling USD 14.2 million of common stock under the earlier prospectus supplement. * Sales will continue under the existing Controlled Equity Offering sales agreement signed March 27, 2026. * Additional shares will be issued off Q32 Bio’s effective Form S-3 shelf registration statement
0 · Reply
GoCoogs
GoCoogs Apr. 24 at 9:20 PM
$QTTB WTH is going on with this after-hours?
0 · Reply
scoon42
scoon42 Apr. 21 at 1:26 PM
$QTTB $8 incoming today IMO!
0 · Reply
Stef_DL
Stef_DL Apr. 21 at 12:58 PM
$QTTB A lot of live in the green party. Let's see what this bring at opening 🤔.
0 · Reply
STACKD0E
STACKD0E Apr. 21 at 12:35 PM
$QTTB $SLDP $PRLD $LOBO
1 · Reply
scoon42
scoon42 Apr. 21 at 12:09 PM
$QTTB Something’s Brewing!
0 · Reply
Kwasy32
Kwasy32 Apr. 20 at 8:08 PM
$QTTB we need news
0 · Reply
scoon42
scoon42 Apr. 20 at 6:08 PM
$QTTB Buying more!
0 · Reply
HoHoHoHum
HoHoHoHum Apr. 14 at 8:38 AM
$QTTB i think this consolidation has helped position it for another run for a higher high — perhaps 10+. Time will tell.
1 · Reply
dhowardu
dhowardu Apr. 12 at 9:04 PM
$QTTB I'm all in. This has the makings of a great moon shot.
0 · Reply
imofacts
imofacts Apr. 10 at 11:51 AM
$QTTB volume is 54 shares premarket so keep that in mind
1 · Reply
imofacts
imofacts Apr. 10 at 11:50 AM
$QTTB
0 · Reply
Black1Panther
Black1Panther Apr. 9 at 10:59 PM
$QTTB give me 6$ so i can sell this shit
0 · Reply
Black1Panther
Black1Panther Apr. 9 at 10:59 PM
$QTTB heading into a nice close
0 · Reply
scoon42
scoon42 Apr. 9 at 8:52 PM
$QTTB $5.40 on yahoo finance after hours! Crazy
0 · Reply
McLarkin
McLarkin Apr. 9 at 5:17 PM
$QTTB shish kebab.. fully loaded here waiting for Ph2 data.... but wish I'd waited another day before loading up...
0 · Reply
ffienimi
ffienimi Apr. 9 at 5:14 PM
$QTTB Q32 Bio entered a Controlled Equity OfferingSM sales agreement with Cantor Fitzgerald to sell common stock through an at-the-market program. * The prospectus supplement covers up to USD 14.2 million of shares that may be offered and sold under the program. * Cantor Fitzgerald will receive a 3% cash commission on gross proceeds from shares sold. * Sales may be made on Nasdaq or other trading markets for the shares, subject to parameters set by Q32 Bio.
1 · Reply
GoCoogs
GoCoogs Apr. 9 at 5:02 PM
$QTTB Brutal sell-off. WTH, man?
0 · Reply